Literature DB >> 14638976

An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients.

Andrew R Pachner1.   

Abstract

A reliable screening assay for anti-interferon beta (IFNbeta) antibodies is needed for patients with multiple sclerosis (MS) receiving IFNbeta therapy. The performance of a new ELISA method, the capture ELISA (cELISA), was assessed by comparing it to a standard IFNbeta ELISA in correlating with neutralizing antibodies measurement in 453 sera from patients with MS. The cELISA outperformed the standard ELISA, and may be a suitable screening assay for anti-IFNbeta antibodies in IFNbeta-treated patients with MS.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14638976     DOI： 10.1212/01.wnl.0000094198.37489.11

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  6 in total

1.  Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients.

Authors:  Andrew R Pachner; Jennifer Brady; Israel Steiner; Kavitha Narayan
Journal:  J Neurol       Date:  2008-11-22       Impact factor: 4.849

Review 2.  Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.

Authors:  Hans-P Hartung; Chris Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Eva Havrdova; Bernhard Hemmer; Jan Hillert; Ludwig Kappos; Bernd Kieseier; Joep Killestein; Christophe Malcus; Manuel Comabella; Andrew Pachner; Huub Schellekens; Finn Sellebjerg; Krysztof Selmaj; Per Soelberg Sorensen
Journal:  J Neurol       Date:  2007-04-24       Impact factor: 4.849

3.  Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.

Authors:  Delphine Bachelet; Signe Hässler; Cyprien Mbogning; Jenny Link; Malin Ryner; Ryan Ramanujam; Michael Auer; Poul Erik Hyldgaard Jensen; Nils Koch-Henriksen; Clemens Warnke; Kathleen Ingenhoven; Dorothea Buck; Verena Grummel; Andy Lawton; Naoimh Donnellan; Agnès Hincelin-Mery; Dan Sikkema; Marc Pallardy; Bernd Kieseier; Bernard Hemmer; Hans Peter Hartung; Per Soelberg Sorensen; Florian Deisenhammer; Pierre Dönnes; Julie Davidson; Anna Fogdell-Hahn; Philippe Broët
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

4.  Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Authors:  Jenny Link; Ryan Ramanujam; Michael Auer; Malin Ryner; Signe Hässler; Delphine Bachelet; Cyprien Mbogning; Clemens Warnke; Dorothea Buck; Poul Erik Hyldgaard Jensen; Claudia Sievers; Kathleen Ingenhoven; Nicolas Fissolo; Raija Lindberg; Verena Grummel; Naoimh Donnellan; Manuel Comabella; Xavier Montalban; Bernd Kieseier; Per Soelberg Sørensen; Hans-Peter Hartung; Tobias Derfuss; Andy Lawton; Dan Sikkema; Marc Pallardy; Bernhard Hemmer; Florian Deisenhammer; Philippe Broët; Pierre Dönnes; Julie Davidson; Anna Fogdell-Hahn
Journal:  PLoS One       Date:  2017-02-07       Impact factor: 3.240

5.  HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.

Authors:  Steve Hoffmann; Sabine Cepok; Verena Grummel; Klaus Lehmann-Horn; Jörg Hackermüller; Jörg Hackermueller; Peter F Stadler; Hans-Peter Hartung; Achim Berthele; Florian Deisenhammer; Ralf Wassmuth; Ralf Wasmuth; Bernhard Hemmer
Journal:  Am J Hum Genet       Date:  2008-07-24       Impact factor: 11.025

6.  Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.

Authors:  Till F M Andlauer; Jenny Link; Dorothea Martin; Malin Ryner; Christina Hermanrud; Verena Grummel; Michael Auer; Harald Hegen; Lilian Aly; Christiane Gasperi; Benjamin Knier; Bertram Müller-Myhsok; Poul Erik Hyldgaard Jensen; Finn Sellebjerg; Ingrid Kockum; Tomas Olsson; Marc Pallardy; Sebastian Spindeldreher; Florian Deisenhammer; Anna Fogdell-Hahn; Bernhard Hemmer
Journal:  BMC Med       Date:  2020-11-04       Impact factor: 8.775
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.